Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
about
Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementPhase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsOral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.Treatment advances in non-Hodgkin's lymphoma.Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.Nucleoside analogues in the treatment of haematological malignancies.New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesEvolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell NeoplasmsCutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.New targets of therapy in T-cell lymphomas.Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab.Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop.Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified
P2860
Q27024076-68EB9900-2479-4CF8-B91C-FEDE6AC26DF6Q33386506-DEDBC763-1ABE-4237-B9F8-CBCF150B7D50Q33396356-F36A6042-9037-4DED-95A8-6BA6C9EF5033Q33409608-90D19327-B189-4068-9688-CA3BC92BDE76Q33425005-A7C3744F-DD4E-4AB6-861A-96FF42C22836Q33431457-99F992A4-34A6-4F13-A5F9-72016BF715A9Q33702181-BCBC6B0B-3315-4791-9011-83C4F56F9F91Q34182179-B5C07C6D-FF98-4DF2-89C0-546384DDC757Q34185007-0B1E562B-3613-4934-8CC9-FACD5E4BFD7EQ34390281-7CCB955E-7903-43C4-876D-E10C61C42951Q34683488-E1EEC9FE-69B4-4AB3-80BC-FF2BEEA0D0C2Q35022833-052DADC6-9BF6-46BB-9DD6-315EFE64F916Q35163220-1892BFDC-497F-431D-BB50-3E484865B232Q36470196-7960AE72-5DF7-4305-BC9E-59057003F35CQ37579991-6E78CAF1-E1EB-4F80-A1DD-D355DBB6FA0CQ37701472-8F4FA9E9-93A1-4697-A5A7-5E922BE0AC0CQ37931041-25AC5238-9E23-430E-BFDA-4E85160EF902Q37944565-BECF4EA4-CAF8-4D4B-A1D6-749BEDC8B509Q38113568-192B1760-9A02-4907-BBD8-7F7B69C5B5D1Q38260926-945BD57E-F496-445A-9C52-18FEC99C65BDQ43249154-774A3C26-2F13-4D6A-A38C-11B59853EC7CQ44876219-0BB1098D-34D2-467C-8419-E88A782487D8Q46061398-8AB5BFAF-0BD2-4B87-BAA3-60D2DD85AA63Q48034709-C2654A67-9A0C-4442-BD97-6370909A956BQ48246246-DEFE4F31-CD4E-4B37-8F50-2BAFD8F2EE95Q48301800-C57B9700-F900-455A-A133-7E5692EA9C01Q48650246-14A55E61-1110-4BF4-9BCD-23F5BFD50474Q48726210-F07A0B8B-4290-4934-8CB8-78D94E1CC6CDQ53153689-5A0863A5-BA72-409C-8FC9-D846DB7A0AD5Q53828417-642F5676-59C9-40B2-9921-B2F240538303Q58482092-29E24D89-B176-484F-AF96-6BEFC6A8CA8F
P2860
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@ast
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@en
type
label
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@ast
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@en
prefLabel
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@ast
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@en
P2093
P356
P1433
P1476
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
@en
P2093
F Gherlinzoni
G F Orcioni
M Bendandi
M Magagnoli
P Albertini
P L Zinzani
S A Pileri
P304
P356
10.1023/A:1008409601731
P577
1998-12-01T00:00:00Z